Eisai Co. said Friday it and Sanofi-Aventis have agreed to terminate on Dec. 31 their marketing alliance in Japan for Sanofi-Aventis’ Rulid antibiotic. From January, Sanofi-Aventis’ Japanese unit will market the drug which is used in treating such symptoms as acne, skin infections and dental infections.
